Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, double-blind, placebo-controlled clinical trial to assess celecoxib as a chemopreventive agent inhibiting UV-induced erythema and cutaneous carcinogenesis as assessed through surrogate biological markers in biopsied skin after exposure of skin in normal volunteers ages 20-60 years old with Fitzpatrick type I, II, III and IV skin to UV-radiation from artificial light sources

Next Previous
X
Search
Trial Profile

A phase II, double-blind, placebo-controlled clinical trial to assess celecoxib as a chemopreventive agent inhibiting UV-induced erythema and cutaneous carcinogenesis as assessed through surrogate biological markers in biopsied skin after exposure of skin in normal volunteers ages 20-60 years old with Fitzpatrick type I, II, III and IV skin to UV-radiation from artificial light sources

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Skin cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Dec 2006 Status change
    • 26 Aug 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top